Healthcare -
Drug Manufacturers - General - NYSE - US
$ 23.97
0.377 %
$ 136 B
Market Cap
17.37
P/E
1. INTRINSIC VALUE
Balance Sheet
Pfizer Inc.
| Current Assets | 50.4 B |
| Cash & Short-Term Investments | 20.5 B |
| Receivables | 14.8 B |
| Other Current Assets | 15.1 B |
| Non-Current Assets | 163 B |
| Long-Term Investments | 2.23 B |
| PP&E | 18.4 B |
| Other Non-Current Assets | 142 B |
| Current Liabilities | 43 B |
| Accounts Payable | 5.63 B |
| Short-Term Debt | 6.95 B |
| Other Current Liabilities | 30.4 B |
| Non-Current Liabilities | 81.9 B |
| Long-Term Debt | 56.7 B |
| Other Non-Current Liabilities | 25.2 B |
EFFICIENCY
Earnings Waterfall
Pfizer Inc.
| Revenue | 63.6 B |
| Cost Of Revenue | 16.4 B |
| Gross Profit | 47.2 B |
| Operating Expenses | 25.6 B |
| Operating Income | 14.9 B |
| Other Expenses | 6.89 B |
| Net Income | 8.05 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Pfizer Inc.
| Net Income | 8.05 B |
| Depreciation & Amortization | 7.01 B |
| Capital Expenditures | -2.91 B |
| Stock-Based Compensation | 877 M |
| Change in Working Capital | -3.07 B |
| Others | 891 M |
| Free Cash Flow | 9.84 B |
Wall Street Analysts Price Targets
Pfizer Inc.
Wall Street analysts predict an average 1-year price target for PFE of $31.7 , with forecasts ranging from
a
low of
$24 to a high of $36 .
PFE Lowest Price Target
Wall Street Target
24 USD
0.13%
PFE Average Price Target
Wall Street Target
31.7 USD
32.25%
PFE Highest Price Target
Wall Street Target
36 USD
50.19%
4. DIVIDEND
ANALYSIS
1.69%
DIVIDEND YIELD
0.43 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Pfizer Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
64.8 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
148 K USD 1
Bought
0 USD 0
0-3 MONTHS
499 K USD 1
3-6 MONTHS
28.2 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
The Dark Side Of Dividend Growth Investing
Dividend growth investing is a powerful way to compound wealth and set yourself up for financial independence. However, it also has some real drawbacks. I share 3 aspects of the dark side of dividend growth investing in this article.
seekingalpha.com
- 6 days ago
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.
zacks.com
- 1 week ago
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
zacks.com
- 1 week ago
I'm Buying Dividend Giants At Huge Discounts
Now is a great time to be an income and value investor, particularly in the energy and pharmaceutical spaces. I highlight 2 undervalued names that provide well-covered dividends with a strong growth outlook. The market seems to be overly rotated on near-term headwinds while ignoring the long-term growth drivers, resulting in a dislocation between price and value.
seekingalpha.com
- 1 week ago
Will Pfizer Slash Its >7% Yielding Dividend? I Wouldn't Rule It Out
Pfizer's >7% dividend yield is attractive, but faces significant risk due to political, regulatory, and business headwinds impacting revenue and profitability. Major threats include U.S. healthcare policy changes, looming patent expiries, misfiring M&A, heavy debt, and over-reliance on COVID vaccine revenues. Management insists the dividend is safe barring a 'catastrophe,' but current challenges feel borderline catastrophic, making a cut plausible if pressures persist.
seekingalpha.com
- 1 week ago
Pfizer: An Offensive Play For A Bear Market
The market has become overly pessimistic on Pfizer, focusing on the patent cliff while ignoring the defensive cash flows and offensive catalysts. This has created a classic value opportunity. A fortress 7% dividend yield provides a powerful downside cushion. We analyze the cash flows to show why this payout is secure and offers a compelling return. We model a 'revenue bridge' to demonstrate how Pfizer's underappreciated pipeline in oncology, vaccines, and I&I is poised to more than fill the gap left by major expirations like Eliquis.
seekingalpha.com
- 1 week ago
Is It Time to Invest in Pfizer? Exploring its 7% Dividend Yield and Growth Potential
Pfizer (NYSE:PFE) stock is a biopharmaceutical firm that had a magnificent breakout in 2021 as the worst of the pandemic sent COVID vaccine demand through the roof.
247wallst.com
- 1 week ago
Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?
PFE's oncology portfolio, boosted by Seagen and late-stage pipeline assets, may fuel growth amid lackluster stock performance.
zacks.com
- 1 week ago
RFK Jr weighs review of vaccines citing aluminum use, Bloomberg News reports
U.S. Health Secretary Robert F. Kennedy Jr. is considering asking a key government vaccine advisory panel to examine vaccines that contain aluminum ingredients, Bloomberg News reported on Wednesday, citing a source familiar with the matter.
reuters.com
- 1 week ago
RFK Jr.'s new vaccine advisors will vote on flu shots containing mercury
A revamped government panel of vaccine advisors appointed by Health and Human Services Secretary Robert F. Kennedy Jr. will soon vote on a shot preservative that contains mercury, which is safely used in some flu jabs but has been incorrectly linked to autism in the past.
cnbc.com
- 1 week ago
3 High-Yield Dividend Stocks Increasing Payouts For Decades
These dividend stocks have high yields and solid upside potential. They also have quality underlying businesses.
247wallst.com
- 1 week ago
50% Off - 2 Dividend Gems With Huge Income And Growth Potential
Investing capital means balancing risk, goals, and timing, especially when markets face uncertainty and shifting global dynamics. I focus on long-term value and income. I highlight two undervalued opportunities with strong dividends that have suffered recent setbacks but show solid growth potential in key sectors like real estate and healthcare. Both picks combine resilience and strategic advantages, offering attractive yields and upside for dividend investors seeking quality income in a complex market environment.
seekingalpha.com
- 1 week ago
8. Profile
Summary
Pfizer Inc. PFE
COUNTRY
US
INDUSTRY
Drug Manufacturers - General
MARKET CAP
$ 136 B
Dividend Yield
1.69%
Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Contact
235 East 42nd Street, New York City, NY, 10017
https://www.pfizer.com
IPO
Date
June 1, 1972
Employees
81000
Officers
Dr. Albert Bourla D.V.M., Ph.D.
Chairman of the Board & Chief Executive Officer
Mr. Douglas M. Lankler
Executive Vice President & Chief Legal Officer
Ms. Payal Sahni Becher
Chief People Experience Officer & Executive Vice President
Dr. Chris Boshoff FMedSci, M.D., Ph.D.
Chief Scientific Officer and President of Research & Development
Ms. Jennifer B. Damico
Senior Vice President, Controller & Principal Accounting Officer
Ms. Sally M. Susman
Executive Vice President & Chief Corporate Affairs Officer
Dr. Michael S. Vincent M.D., Ph.D.
Senior Vice President and Chief Scientific Officer of Inflammation & Immunology
Ms. Lidia L. Fonseca
Executive Vice President and Chief Digital & Technology Officer
Ms. Francesca M. DeMartino
Chief Investor Relations Officer
Mr. David M. Denton
Chief Financial Officer & Executive Vice President